Stockwinners Market Radar for October 28, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:24 EDT Lone Star funds to sell AOC tot Nippon Paint - Lone Star Funds announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell AOC, a leading global specialty chemicals company, to Nippon Paint Holdings. Under Lone Star's stewardship, AOC invested in its core business systems, including commercial excellence, innovation, procurement and manufacturing efficiency, to drive earnings growth. AOC also invested in the expansion of its executive leadership team, broadening the capabilities of the team to efficiently manage the global enterprise. AOC is poised to capitalize on its next leg of growth, supported by a well-capitalized asset base and a world-class management team. The transaction is subject to certain closing adjustments and conditions, including regulatory clearances, and is expected to close in the first half of 2025.

19:50 EDT Movano Inc trading halted, news pending

18:54 EDT Veea announces collaboration with Aecom and Amazon - In partnership with the Colombian government, Veea (VEEA), is collaborating with O.N.E. Amazon (AMZN), and AECOM (ACM) to deploy a technologically advanced, multidimensional solution composed of hybrid edge-cloud computing and communications products in a protected conservation area of the Government of Colombia. The goal of the deployment is to monitor and analyze rainforest health and digitally connect every hectare to deliver sustainable economic and social benefits to rural communities. This "Internet of Forests" initiative underscores each entity's commitment to the UN's Sustainable Development Goals which seek to promote prosperity while protecting the planet. The advanced technological framework of IoF is designed not only to help preserve the ecosystem of Chiribiquete, Colombia's largest national park and a UNESCO World Heritage site, but also to reveal the intrinsic value of one of the planet's most vital natural resources, seeking sustainable management and protection of the Amazon rainforests for future generations. The IoF initiative will enable detailed monitoring and data collection, from ground sensors and cameras installed in the rainforest, with collected data processed locally on VeeaHub devices in a mesh cluster installed in carefully selected zones throughout the rainforest with a satellite backhaul.

17:53 EDT Icahn Enterprises down 1.3% following CVR Energy dividend suspension - The Fly notes that CVR Energy (CVI) is hedge fund Icahn Enterprises' (IEP) largest holding.

17:36 EDT Digital Ally receives Default and Reservation Letter from counsel for Softforge - In a regulatory filing, Digital Ally stated, "As previously disclosed, on March 1, 2024, Digital Ally entered into a Note Purchase Agreement, by and between the company, Kustom Entertainment, Inc., a Nevada corporation and wholly-owned subsidiary of the company, and Mosh Man, LLC, a New Jersey limited liability company, pursuant to which the Borrowers issued to the Purchaser a Senior Secured Promissory Note, as modified pursuant to that Letter Agreement dated July 13, 2024, as further modified pursuant to that Letter Agreement dated September 12, 2024, as further modified pursuant to that Amended and Restated Promissory Note, dated September 25, 2024. In connection with the Agreement, the Borrowers entered into a Security Agreement by and between the Borrowers, as grantor, and the Purchaser, as grantee. On October 22, 2024, the company received a Default and Reservation Letter from counsel for Softforge Innovation, the administrative agent for the Note, (i) notifying the company that it is in default under the Note for, among other reasons, failing to make a $100,000 payment that was due on October 10, 2024, (ii) accelerating all principal and interest payments due under the Note, and (iii) demanding the Borrowers enter into a lockbox control agreement within ten business days of the date of the Default Notice. As of the date of this report, the outstanding obligation of the company under the Note is approximately $1,600,000. On October 24, 2024, the company received a Notice of UCC Article 9 Public Sale from counsel to Softforge notifying the company that it intends to conduct a public sale of the collateral securing the company's obligations under the Note and Security Agreement at 11:00 a.m. ET on November 5, 2024. The company has notified Softforge that it disputes the claims made in the Default Notice and the Sale Notice and demanded that Softforge immediately rescind the Sale Notice and cancel the public sale. The company intends to vigorously defend its rights, including by seeking injunctive relief and damages against Softforge."

17:27 EDT Lockheed Martin awarded $1.24B Army contract modification - Lockheed Martin was awarded a $1.24B modification to a contract for UH-60M aircraft. Work will be performed in Stratford, Connecticut, with an estimated completion date of December 31, 2027. FY25 Foreign Military Sales funds in the amount of $1.24B were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:14 EDT Ford says it has a 'growing' export business - Says China and its exports are contributing $600M to company's EBIT this year. Says seen "huge" surge in interest online in Ford Power Promise. Says Maverick and Bronco launching in Q4. Says Navigator launching early next year. Comments taken from Q3 earnings conference call.

17:09 EDT Dream Finders Homes to acquire Alliant National - Alliant National Title Insurance Company and affiliate announced that it has entered into a definitive agreement to be acquired by Dream Finders Homes. Presidio Investors acquired Alliant National in 2018 and has been instrumental in helping the company establish robust internal processes, expand geographic reach, improve operational efficiency, and drive technology innovation. In 2023, Alliant National created a leading fraud detection tool designed specifically to streamline the flow of a real estate transaction. This unique solution is fully customizable for title agencies and has robust AI-enabled fraud prevention capabilities. The closing of this transaction is subject to regulatory approvals.

17:02 EDT VF Corp. sees Q3 gross margin up year-over year - Says Q2 was largely in line with expectations. Says NorthFace backpacks performed well in back-to-school season. Says ended Q2 with inventory down 13%. Says expects more variability in the tax rate by quarter. Says expects Q4 to show another quarter of sequential improvement in revenue trends. Says wholesalers have given positive feedback on Vans. Comments and guidance taken from Q2 earnings conference call.

16:52 EDT New Mountain Finance extends $50M share repurchase program - New Mountain Finance announced that the company's board of directors authorized an extension of a previously established stock repurchase program. Pursuant to the repurchase program, the company can repurchase up to $50M worth of its common stock at the discretion of NMFC's management team. The repurchase Program was set to expire on December 31, 2024, but the Company's board of directors elected to extend the Repurchase Program through December 31, 2025. Unless further extended by NMFC's board of directors, the company expects the repurchase program to be in place until the earlier of December 31, 2025 or until $50M worth of NMFC's outstanding shares of common stock have been repurchased. To date, approximately $2.9M worth of repurchases have been made by the company under the repurchase program. The company's board of directors authorized the extension of the repurchase program because it believes that sustained market volatility and uncertainty may cause NMFC's common stock to be undervalued from time to time.

16:38 EDT FactSet to acquire Irwin, terms undisclosed - FactSet announced it has agreed to acquire Irwin, an investor relations and capital markets solution for public companies and their advisors. Founded in 2017 and based in Toronto, Canada, Irwin is an investor relationship management platform that streamlines investor relations by connecting people, data, and insights into one platform. The transaction is expected to close during FactSet's first quarter fiscal 2025 and is not expected to have a material impact on FactSet's fiscal 2025 results.

16:35 EDT Energy Transfer LP raises quarterly distribution to 32.25c per share - Energy Transfer LP announced an increase in its quarterly cash distribution to 32.25c per Energy Transfer common unit for the third quarter ended September 30, 2024. This cash distribution per Energy Transfer common unit will be paid on November 19, 2024 to unitholders of record as of the close of business on November 8, 2024, and is an increase of 3.2 percent as compared to the third quarter of 2023.

16:33 EDT Jack Henry reports Q1 deconversion revenue $3.7M - Jack Henry & Associates announced that deconversion revenue for the fiscal first quarter, ended September 30 was $3.7M. Based on these results, deconversion revenue estimates remain at $16M for full year fiscal 2025 guidance.

16:30 EDT Central Plains Bancshares adopts repurchase program - Central Plains Bancshares announced that its Board of Directors has adopted a stock repurchase program. Under the repurchase program, the Company may repurchase up to 200,000 shares of its common stock, or approximately 5.0% of the current outstanding shares. Repurchases will be made no sooner than the termination of the Company's regular trading blackout period, and consistent with the Company's trading policies. The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission.

16:29 EDT FG Financial will effect a one-for-twenty-five reverse stock split October 31 - Fundamental Global announced that it will effect a one 1 -for-twenty-five 25 reverse stock split of its outstanding common stock, effective October 31 at 5:00 p.m., Eastern Time. The Company's common stock should begin trading on a split-adjusted basis at the commencement of trading on November 1 under the Company's existing trading symbol, "FGF." The Company's common stock has been assigned a new CUSIP number, 30329Y 304, in connection with the reverse stock split.

16:22 EDT Ellington Financial estimates book value per share of $13.66 as of September 30 - Ellington Financial Inc. announced its estimated book value per share of common stock of $13.66 as of September 30, 2024. This estimate includes the effect of the previously announced monthly dividend of $0.13 per share of common stock, payable on October 25, 2024 to holders of record on September 30, 2024, with the same ex-dividend date.

16:20 EDT Ross Stores names James Conroy CEO - Ross Stores announced that its Board of Directors has appointed James Conroy (54), a seasoned retail CEO, as Chief Executive Officer, succeeding Barbara Rentler effective February 2, 2025. Initially, Mr. Conroy will join the Company on December 2, 2024 as Chief Executive Officer - Elect, when he will also become a member of the Board of Directors, reporting to Executive Chairman Michael Balmuth. Upon becoming CEO, he will report directly to the Company's full Board of Directors.

16:17 EDT VF Corp. sees FY25 free cash flow from continuing ops plus asset proceeds $425M - "For FY25 VF expects free cash flow from continuing operations plus proceeds from non-core physical asset sales of approximately $425 million, with core fundamentals in line with previous guidance. Relative to the original full year guidance of $600 million, the change reflects the sale of Supreme and additional reinvestment initiatives in the second half of FY25, which are partially offset by the greater than anticipated proceeds for non-core physical asset sales," the company stated.

16:16 EDT COPT acquires land for data center shell development - COPT Defense Properties acquired a 365-acre land parcel near Des Moines, Iowa in late September for $32 million to expand its data center shell program. The existing zoning on the land allows for data center development and initial plans indicate that the site can accommodate approximately 3.3 million square feet of development, supported by an estimated 1 gigawatt of power capacity. Also, late in the third quarter, the Company acquired an 80,000 square foot building at 3900 Rogers Road in San Antonio, Texas for $17 million. The building was vacant upon acquisition, and the Company subsequently executed two leases with the U.S. Government to occupy the entire building, which it expects to commence in the second quarter of 2025. The Class A office building was constructed in 2005, and is located 5 miles northwest of the Company's approximately 1.0 million square foot campus, which is 100% leased and occupied.

16:16 EDT F5 Networks board authorizes additional $1B for stock buyback - F5 announced that its Board of Directors has authorized an additional $1 billion for its common stock repurchase program. This new authorization is incremental to the $422 million remaining in the existing program.

16:13 EDT Ford cuts FY24 adjusted EBIT view to about $10B from $10B-$12B - Backs FY24 adjusted FCF view $7.5B-$8.5B. Cuts FY24 capital spending view to $8B-$8.5B from $8B-$9B.

16:10 EDT Murchison nominates two candidates to Nano Dimension's board - Murchison, a significant shareholder with approximately 7.1% of the outstanding shares of Nano Dimension (NNDM), announced it has nominated two director candidates - Robert (Bob) Pons and Ofir Baharav - for election to the Nano Board of Directors at the upcoming 2024 Annual General Meeting of Shareholders, scheduled for December 6, 2024: "For the past two years, we have been advocating for changes in the Nano boardroom that are critical in order to protect and create long-term shareholder value. In March 2023, Nano shareholders sent a clear message when they voted overwhelmingly at the special general meeting we called in favor of removing CEO Yoav Stern, Oded Gera, Igal Rotem and Yoav Nissan-Cohen from the Board. Despite 85% of voting shareholders voting to remove them, Messrs. Stern, Gera and Nissan-Cohen have refused to recognize these results and depart the Board. Since then, Nano has gone to great lengths to ignore this clear desire for change and disenfranchise shareholders, including by manipulating the voting process at last year's annual general meeting of shareholders and weaponizing the legal systems in Israel and the U.S. at shareholders' expense. While we are confident that the merits of our case will prevail, we cannot wait for the Israeli Court's decision. Despite Nano's so-called "refreshment" of the Board, it is clear to us that the problems identified by Murchinson persist and the Board remains subservient to Mr. Stern. Nano's Board has demonstrated that it is unable to improve the Company's valuation. The Company's share price is stagnant and the Board, having spent approximately $160 million on share repurchases, appears to have no ideas to improve it. The Board has shown that it is incapable of holding management accountable. The proposed compensation package for Mr. Stern, which we find offensive because, among other things, it is misaligned with actual performance, confirms that the Board is not protecting shareholders' interests nor properly overseeing management. The Board's actions reveal that it lacks the necessary judgment to use Nano's cash and other resources responsibly. Between the related-party acquisition of DeepCube from two sitting directors at an inflated value in 2021, the overpriced, misguided acquisitions of Desktop Metal, Inc. (DM) and Markforged Holding Corp. (MKFG), and management's demonstrated inability to integrate acquired businesses and generate synergies, there is compelling evidence that additional independent voices with M&A experience are needed. When a publicly traded company is valued at a discount to its cash, shareholders are signaling that they do not believe the company's leadership can create value. This persistent negative enterprise value reveals that the Nano Board either does not care or is not able to convince shareholders otherwise."

16:09 EDT Boot Barn names John Hazen interim CEO - Boot Barn announced that John Hazen, the Company's current Chief Digital Officer, will assume the role of Interim CEO, effective November 22, 2024. Mr. Hazen joined the Company in 2018 with responsibility for e-commerce, marketing, and the customer experience. Additionally, Peter Starrett, the Company's current Chairman of the Board of Directors, will assume the role of Executive Chairman, effective November 22, 2024. Mr. Conroy will remain with the Company through November 22, 2024 to assist with an orderly transition.

16:06 EDT Boot Barn reports Q2 SSS up 4.9% y/y - Same store sales increased 4.9% compared to the prior-year period, comprised of an increase of 4.3% in retail store same store sales and an increase of 10.1% in e-commerce same store sales.

16:03 EDT Calix says 'confident' in sequential growth - The company said, "With lead times for appliances now at a post-pandemic new normal and BEAD applications well underway, we are confident in our sequential growth, and we are excited by the multi-year outlook for our business. We remain focused on growing our footprint by adding to our BEP customer base and expanding the reach of our platform, cloud and managed services across their subscribers."

15:49 EDT Rapid7 rises about 6% after Reuters report of exploring options - Shares of Rapid7 (RPD) are on the rise after Reuters reported that the cybersecurity company is exploring options with its investment bank advisors at Goldman Sachs (GS) and JPMorgan (JPM) after attracting acquisition interest from buyout firms. The Boston-based company is in early talks with private-equity firms including Advent, Bain Capital and EQT, and is exploring a potential sale, sources familiar with the matter told Reuters' Milana Vinn, though they added that discussions may not lead to a deal and Rapid7 could opt to stay independent, according to Reuters. Rapid7 shares are up roughly 6% near the close. Reference Link

15:37 EDT Serko to acquire GetThere, Sabre's corporate online booking tool - Sabre and Serko Limited announced that they have entered into a definitive agreement, pursuant to which Serko will acquire GetThere L.P., Sabre's business travel management solution. "Under the new partnership, Serko will acquire the GetThere business and work with Sabre to collaborate on the development of new product capabilities for corporate customers, as well as the growth and expansion of the companies' relevant customer base - all with the goal of empowering and delivering greater value to travel management companies, corporate travel buyers, and, ultimately, business travelers. The partnership also defines a joint approach to commercial, sales and marketing initiatives to seek to facilitate growth in North America and beyond. Upon closing of the deal, which is subject to customary conditions, ownership of the GetThere business will be transferred to Serko, including the GetThere solution and certain intellectual property used by GetThere in the operation of its business; the substantial expertise and deep domain knowledge of the GetThere team members; as well as a strong global customer base that includes many blue-chip companies in North America. Serko will continue to operate and sell under the GetThere brand and the parties will work together on transitional arrangements to ensure customers experience continuity of product, service and management. Sabre does not expect the sale of the GetThere business to have a significant impact on its revenue, Adjusted EBITDA or free cash flow in 2024 and thereafter," the companies stated.

13:04 EDT Nexstar to acquire assets of WBNX-TV/TV55 in Cleveland, terms not disclosed - Nexstar Media Group has agreed to acquire the assets of WBNX-TV/TV55 in Cleveland, Ohio, from the Winston Broadcasting Company. The acquisition will create a duopoly for Nexstar in the nation's 19th largest television market, where the company already owns and operates WJW-TV. WBNX-TV is currently an independent television station and will, under Nexstar's ownership, become an affiliate of The CW Network on Sept. 1, 2025. The transaction, subject to regulatory and other customary approvals, is expected to close in 2025 and will be accretive to Nexstar's operating results pro forma for the conversion to a CW affiliation. Financial terms of the transaction were not disclosed.

12:56 EDT Mitsubishi Electric Power Products to build manufacturing plant in Pennsylvania - Mitsubishi Electric Power Products, in collaboration with its parent company Mitsubishi Electric Corporation in Japan, announced an $86M investment in advanced switchgear production and power electronics in the U.S. This investment is driven by the increasing demand for transmission and distribution grid products as the U.S. moves toward renewable energy and decarbonization goals. MEPPI will construct a new approximately 160,000 square foot Advanced Switchgear Factory in Western Pennsylvania, marking MEPPI's first new manufacturing facility in over a decade. Initially, the factory will focus on the production of both vacuum and gas circuit breakers. As the factory scales its operations, it will transition to predominantly manufacturing vacuum circuit breakers, aligning with MEPPI's commitment to meet the evolving needs of U.S. electric utilities and support the nation's broader decarbonization efforts. Upon reaching full capacity, it is anticipated that the facility will employ more than 200 full-time workers. MEPPI will also expand and upgrade its existing facilities in Warrendale, PA, with investments in power electronics and test labs. The company received a funding proposal from the Department of Community and Economic Development for a $4M Redevelopment Assistance Capital Program grant and a $2.75M Pennsylvania First grant.

12:41 EDT TMT Acquisition Corp trading halted, volatility trading pause

12:01 EDT Nuscale Power rises 19.3% - Nuscale Power is up 19.3%, or $3.55 to $21.96.

12:01 EDT Cemex falls -10.3% - Cemex is down -10.3%, or -61c to $5.37.

12:00 EDT Philips falls -16.7% - Philips is down -16.7%, or -$5.29 to $26.38.

11:10 EDT QNTM Stock trading halted, volatility trading pause

11:03 EDT Apple announces new iMac, featuring M4 chip and Apple Intelligence - Apple announced the new iMac, featuring the M4 chip and Apple Intelligence, in its "stunning, ultra-thin design." The company stated: "With M4, iMac is up to 1.7x faster for daily productivity, and up to 2.1x faster for demanding workflows like photo editing and gaming, compared to iMac with M1.1 With the Neural Engine in M4, iMac is the world's best all-in-one for AI and is built for Apple Intelligence, the personal intelligence system that transforms how users work, communicate, and express themselves, while protecting their privacy. The new iMac is available in an array of beautiful new colors, and the 24-inch 4.5K Retina(R) display offers a new nano-texture glass option.2 iMac features a new 12MP Center Stage camera with Desk View, up to four Thunderbolt 4 ports,3 and color-matched accessories that include USB-C. Starting at just $1,299, now with 16GB of unified memory, the new iMac is available to pre-order today, with availability beginning Friday, November 8."

10:08 EDT Brightside selects Helix by Q2 to migrate BaaS program - Helix by Q2 announced its partnership with Brightside. Brightside's savings, checking and business operations accounts, are now powered by Helix's banking as a service solution.

10:04 EDT eXp Realty enters strategic partnership with Sisu - eXp Realty announced a strategic relationship with Sisu designed to enable eXp Realty's extensive network of agents in the United States and Canada to access real-time insights through Sisu as part of their existing fee structure. Building on an already robust working relationship where many top-producing eXp Realty teams have leveraged the Sisu platform to enhance their operations, this formal strategic relationship marks a significant advancement in how agents can leverage Sisu tools.The Sisu integration will offer all North American agents and teams unparalleled insights into their data, empowering them to make informed business decisions, identify areas for improvement and capitalize on opportunities. Team leaders will be able to set goals, monitor team performance, coach agents and foster competition through leaderboards and contests.

10:00 EDT Borr Drilling falls -9.4% - Borr Drilling is down -9.4%, or -44c to $4.26.

10:00 EDT Sunnova Energy rises 9.6% - Sunnova Energy is up 9.6%, or 51c to $5.80.

10:00 EDT Beyond rises 12.1% - Beyond is up 12.1%, or 77c to $7.14.

09:48 EDT Borr Drilling falls -7.9% - Borr Drilling is down -7.9%, or -37c to $4.33.

09:47 EDT Offerpad Solutions rises 9.0% - Offerpad Solutions is up 9.0%, or 26c to $3.08.

09:47 EDT Azul rises 10.7% - Azul is up 10.7%, or 30c to $3.10.

09:35 EDT Autonomix Medical Inc trading resumes

09:31 EDT Genprex collaborators present positive preclinical data on the use of Reqorsa - Genprex announced that research collaborators delivered poster presentations at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held October 23-25, 2024 in Barcelona, Spain. The collaborators presented posters on positive preclinical data from studies of Genprex's lead drug candidate, Reqorsa Gene Therapy for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma. "We are pleased by this promising preclinical data, presented before a prestigious audience of oncology researchers, of Reqorsa's potential in serious and difficult to treat cancers including KRAS G12C mutant lung cancer, mesothelioma, and glioblastoma," said Ryan Confer, President and CEO at Genprex. "The role of TUSC2 in lung cancer has been well established, and TUSC2 restoration is being evaluated clinically. However, we are highly encouraged by our preclinical programs expanding the potential use of Reqorsa to treat a variety of cancer indications, where patient populations have unmet medical needs."

09:30 EDT Autonomix Medical Inc trading halted, volatility trading pause

09:19 EDT Terreno Realty announces development start in Hialeah, FL - Terreno Realty Corporatio announced that it has commenced construction of Countyline Corporate Park Phase IV Building 34 in Hialeah, Florida. Building 34 of Terreno Realty Corporation's Countyline Corporate Park is a 220,000 square foot 36-foot clear height rear-load industrial distribution building on 13.0 acres with 76 dock-high and two grade-level loading positions and parking for 188 cars. Building 34 has been 70% pre-leased to a cruise ship industry provider of non-perishable food items and food service supplies commencing with building completion and tenant build-out, expected to be in the third quarter of 2025, and expiring February 2033. Building 34 is expected to achieve LEED certification, the total expected investment is $55.9 million and the estimated stabilized cap rate is 5.7%.

09:17 EDT BigBear.ai implements biometricboarding Solutions for Denver International Air - BigBear.ai announced a successful installation of veriScan , BigBear.ai's biometric verification solution, at the Denver International Airport DEN . veriScan is now deployed at 14 international departure gates at DEN, impacting the boarding process for over 46,600 international departing passengers. BigBear.ai's veriScan offers a seamless experience for proper identification of individuals traveling internationally in settings with required security protocols. veriScan allows airlines at the Denver International Airport to reduce boarding times. The facial biometric process is voluntary for U.S. citizens. ... the U.S. Customs and Border Protection CBP is congressionally mandated to implement a biometric entry-exit system. Using CBP's Traveler Verification Service, veriScan captures and transmits the traveler's image to CBP during the boarding process for identity verification. veriScan has processed over 28 million passengers since its inception in 2018. "We are thrilled to see positive results early on from the implementation of veriScan at Denver International Airport," said Kevin McAleenan, President

09:15 EDT Safe Pro AI launches SpotlightAI 3.0 solution - Safe Pro Group announced its Safe Pro AI unit has launched SpotlightAI 3.0, the next generation of its patent-pending AI solution powered by Amazon Web Services. SpotlightAI is currently in use in Ukraine by multiple international humanitarian mine action organizations and government entities. As of October, SpotlightAI powered by AWS, has processed over 757,516 drone images in Ukraine, confirming the presence of over 6,151 explosive remnants of war detected in 3,135 hectares of land. On the AWS cloud, each image can be processed in a blink of eye utilizing advanced proprietary machine learning algorithms and AWS hyper-compute versus requiring a trained human analyst who could take several minutes to review individual images in an attempt to locate and detect mines and ERW as small as the palm of a hand. In the Ukraine Rapid Damage and Needs Assessment Report it is estimated that 17 million hectares of land are contaminated with explosive ordnance. SpotlightAI, powered by AWS Hyper Scale, can drastically impact this unprecedented challenge compared to manual, human-based analysis of drone imagery of millions of hectares of land which could take decades.

09:11 EDT Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - Tharimmune presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadelphia. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease. The primary outcome measure was to determine the safety and tolerability of a single buccal dose of TH104 in these patients. The data presented included adverse events as well as assessment of patients using the Clinical Opiate Withdrawal Scale. The COWS is an 11-item clinician-administered scale that can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor them over time. The summed score for the complete scale can be used by clinicians to determine the stage or severity of withdrawal, and to assess the level of any physical dependence. This study enrolled two types of CLD patients categorized as Child-Pugh A and Child-Pugh B. The Child-Pugh score is a system for assessing the prognosis and necessity of transplant in CLD that provides a forecast of the increasing severity of a patient's liver disease and expected survival rate. The score is determined by scoring clinical measures of liver disease and the possibility of eventual liver failure, with Class A indicating mild liver disease and Class B indicating moderate liver disease with a one-to-five-year survival rates of 95% and 75%, respectively. There were no patients enrolled in this study with the most severe Child-Pugh C classification. The mean baseline WI-NRS scores in Groups A and B were 4.33 and 6.17, respectively, translating to moderate-to-severe chronic pruritus at the start of the study. The mean baseline itch score for all 12 subjects was 5.25. At one hour post-dosing with TH104, Group A and Group B had a mean decline in WI-NRS scores of 26.8% and 19.0%, respectively, and continued to decline two hours post-dose by 42.3% and 21.7%, respectively. Both cohorts continued to improve in mean itch scores at the four-hour and eight-hour time points, including the combined total subjects. At 24-hours post dosing, Group A and Group B achieved a mean decline of 30.7% and 35.2%, respectively, in pruritus scores. The mean reduction in itch scores for all 12 subjects 24 hours after a single dose of TH104 was 33.3%. There were no deaths, other serious adverse events or other significant adverse events reported during the entire study. There were no new adverse events during the entire study, with events correlated with previous studies and a safety profile consistent with the literature for the active ingredient in TH104. The Company plans to initiate a Phase 2 multiple-ascending dose trial in the coming months to assess the safety and tolerability of TH104, which will assess the change from baseline in WI-NRS scores to evaluate chronic pruritus in PBC patients. The Company expects topline data in 2025 and is engaging with both U.S. and EU regulatory authorities.

09:07 EDT BioCardia completes last protocol specified follow-up visit in CardiAMP HF - BioCardia announced the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized, double-blinded, placebo procedure controlled, multi-center pivotal clinical trial for the treatment of heart failure of reduced ejection fraction, HFrEF. "Phase I and II trial results and the interim Phase III trial results have shown trends toward patient benefit across most outcome measures. These results support our belief that the CardiAMP autologous, minimally invasive, cell therapy has great promise to provide a meaningful benefit for patients suffering from heart failure," said Peter Altman, PhD, CEO of BioCardia. "We will soon complete data monitoring and then unblind the study to perform analysis for safety and effectiveness."

09:06 EDT eHealth receives Hitrust i1 certification for managing data protectione - eHealth (EHTH) has successfully achieved Hitrust i1 certification for its carrier integration platform hosted through Amazon (AMZN) Web Services. Hitrusti1 certification certification strengthens credibility among clients, partners, and stakeholders.

09:03 EDT Neo-Concept establish joint venture with Liwa Trading Enterprises - Neo-Concept International Group announces the successful establishment of its joint venture, Lineowa Fashion and Lifestyle, with Liwa Trading Enterprises LLC. This collaboration marks a significant step in NCI's strategy to enhance its footprint in the UAE and the Gulf Cooperation Council, GCC, retail markets. "Our partnership with Liwa empowers us to bring Les100Ciels to a wider audience," stated Ms. Eva Siu, Chairlady of the Board of Directors and Chief Executive Officer of NCI. "We're excited to offer our customers an exceptional shopping experience both online and in-store."

09:03 EDT First Northwest Bancorp, First Fed Bank announce consent order termination - First Fed Bank, the wholly owned subsidiary of First Northwest Bancorp, announced that on October 23, 2024, the Federal Deposit Insurance Corporation terminated the Consent Order issued to the Bank that was effective November 21, 2023. The termination of the Consent Order follows the Bank's successful resolution of the deficiencies in the Bank's compliance program that was the subject of the Order.

09:01 EDT Arthur J. Gallagher acquires Filos Agency - Arthur J. Gallagher acquired Long Beach, New York-based Filos Agency. Terms of the transaction were not disclosed. Filos Agency is a retail property/casualty insurance agency serving New York area businesses and individuals. Thomas Costantakos and his team will continue to operate out of their current location as part of Gallagher Agency Alliance under the direction of Jen Tadin, head of Gallagher Select, its U.S. property/casualty operations for small businesses.

08:51 EDT enVVeno Medical initiates six-month pre-clinical GLP study of enVVe - enVVeno announced the start to its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The first wave of implants, for the long-term subjects, was successfully completed, with the final wave for the shorter-term subjects scheduled for December. The GLP study is a prerequisite to enVVeno seeking IDE approval from the U.S. Food and Drug Administration to begin the enVVe U.S. pivotal study. The Company expects to be in a position to file for IDE approval for the enVVe pivotal trial mid-next year. enVVeno's lead product is the VenoValve, a surgical replacement venous valve for patients suffering from severe Chronic Venous Insufficiency caused by incompetent valves in the deep venous system. The Company estimates that there are approximately 2.5 million candidates each year in the U.S. for the VenoValve. enVVe, a next-generation, transcatheter based replacement venous valve, would appeal to an even larger market in terms of both patients and physicians. Severe deep venous CVI is a debilitating disease that is most often caused by blood clots in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase. Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. enVVeno expects to file its PMA application seeking approval from the U.S. Food and Drug Administration to market and sell the VenoValve, and to release the definitive data that supports the PMA application in Q4 of this year. Beginning early next year, the Company will begin to implement its plans to transition from being a development stage company to a commercial entity, and to complete all of the additional non-clinical testing for enVVe that is necessary to file for IDE approval.

08:49 EDT Rush Street Interactive introduces PropPacks - This NBA season, the team at Rush Street Interactive, which operates the BetRivers Sportsbook, unveils PropPacks. The simplicity of the new digital game, combined with the chance for large payouts, will appeal to both seasoned bettors and those new to sports betting. "PropPacks, which is exclusively available on RSI's platform to BetRivers Sportsbook players, will give NBA fans an additional thrill by offering extra bonus opportunities on their SGP bets," said Richard Schwartz, CEO at RSI. "The player card game makes watching the action even more exciting by offering bettors at all levels, from those placing a bet for the first time to experienced sports wagerers, more ways to win from existing SGP bets at no additional cost to our bettors. PropPacks reinforces our dedication to put our players first by creating value for them while elevating the betting experience in fun and exciting ways."

08:47 EDT Pineapple Energy's SUNation announces strategic partnership with Radial Power - SUNation, the subsidiary of Pineapple Energy, announced a strategic partnership with Houston, Texas-based Radial Power, a key player within distributed energy and a provider of sustainability solutions for commercial and industrial real estate asset owners. This strategic partnership will harness the combined expertise of both companies to deliver innovative renewable energy solutions. It also marks a significant step in SUNation's expansion beyond its traditional New York footprint, positioning the company for broader geographic growth.

08:46 EDT CompoSecure achieves ISO 27001 certification for premium card manufacturing - CompoSecure achieved ISO/IEC 27001 certification for its premium card manufacturing operations. ISO/IEC 27001 is the globally recognized information security management system standard. It sets out the criteria for organizations to ensure the confidentiality, integrity and availability of sensitive information, offering rigorous standards for risk management and security controls.

08:45 EDT Westwood Holdings Group invests in venture with ETF leader Ben Fulton - Westwood Holdings Group announced that Westwood has invested in a new venture with exchange-traded-fund industry leader Ben Fulton to expand Westwood's existing ETF platform to include new, highly innovative strategies developed under a new stand-alone entity called WEBs Investments, which stands for "Westwood Engineered Beta." WEBs is an investment adviser registered with the U.S. Securities and Exchange Commission. Westwood will invest in WEBs and provide distribution resources and administrative support to WEBs, leveraging its more than 40 years in the investment management industry. Westwood will have the option to acquire WEBs in the future if the entity achieves certain growth milestones. "In the second quarter of this year, we took the first steps towards achieving our vision of building out our ETF platform with the rollout of two Energy ETFs, both of which were well received by the market and our clients," said Brian O. Casey, CEO"Our partnership with Ben and his team will greatly accelerate our path to meet the needs of investors who have expressed growing interest in ETF products. We believe that combining Ben's ETF product development track record and vision with Chris Doran's sales experience and relationships in the ETF space, along with the resources of our Westwood distribution team, will be a powerful combination to drive the growth of our partnership. Our goal will be to deliver new and innovative products in the 'white spaces' where we can secure first-mover advantage with less competition-always looking toward the next phase of growth to deliver value to our clients, our shareholders and our firm."

08:44 EDT Wearable Devices regains compliance with Nasdaq minimum bid price rule - Wearable Devices announced that it has received a written notice from Nasdaq Stock Market, indicating that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

08:42 EDT Kezar Life Sciences announces 1-for-10 reverse stock split - Kezar Life Sciences announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten . The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29. The Company's common stock will begin trading on a post-split basis at the market open on October 30, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 18 to be effected at the Board's discretion within approved parameters. Following the Annual Meeting, the final ratio was approved by the Company's Board on September 23 .

08:40 EDT RealReal appoints Levesque as Chief Executive Officer - The RealReal announced that its Board of Directors has appointed Rati Sahi Levesque, The RealReal's President and Chief Operating Officer, COO, as President and Chief Executive Officer, CEO, and as a member of the Board, effective immediately. Levesque succeeds John Koryl, who has departed from the Company and no longer serves on the Board.

08:39 EDT Nexalin announces study on AD, DIFS published in Journal of Alzheimer's Disease - Nexalin Technology announced publication of a landmark study titled, "Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer's Disease After Transcranial Alternating Current Stimulation, tACS,: A Resting-State Functional Magnetic Resonance Imaging Study" in the Journal of Alzheimer's Disease. This study builds on recent findings from Nexalin's Deep Intracranial Frequency Stimulation, DIFS, research and further highlights the effectiveness of non-invasive neurostimulation in enhancing brain function and improving cognitive performance in patients with mild Alzheimer's disease, AD. This new research involved 46 patients, randomly assigned to receive either real DIFS or sham treatment for 30 one-hour sessions over a period of three weeks. Resting-state functional magnetic resonance imaging was used to track changes in brain activity, showing that Nexalin's proprietary DIFS technology significantly alters neuronal activity in key regions of the brain, providing a non-pharmacological, safe treatment option for Alzheimer's.

08:37 EDT Lisata Therapeutics entered research agreement with University of Cincinnati - Lisata Therapeutics announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting its use in otherwise healthy young women. Under the agreement, the University of Cincinnati will conduct the research, while Lisata will provide both funding and certepetide.

08:34 EDT GreenPower Motor receives $18.5M EPA order for 50 electric school buses - GreenPower Motor has finalized the particulars for the order for 50 all-electric Type D BEAST and Mega BEAST and Type A Nano BEAST and Nano BEAST Access school buses for seven county school districts in West Virginia funded by the EPA Clean School Bus Program. The order is through GreenPower's West Virginia dealer. GreenPower collaborated with its Dealer and Highland Electric Fleet and they, collectively, made depot visits to each school district to establish their needs. They then provided guidance on the charging infrastructure, drafted the application, met with the school districts' Boards of Education for approval, and submitted the grant application to the EPA.

08:33 EDT Danimer Scientific announces second circuit court affirms dismissal of lawsuit - Danimer Scientific announced that the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In re Danimer Scientific, Inc. Securities Litigation. Subsequently, the plaintiffs in the three shareholder derivative cases that had been pending in state and federal courts in Delaware, which cases had been stayed pending the outcome of the Second Circuit case, dismissed their complaints.

08:31 EDT Nature's Miracle enters Cooperation Agreement with Robostreet - Nature's Miracle announced it has entered into a Cooperation Agreement with Robostreet to order a total of 150 LS450 electric trucks from Robostreet. As part of the agreement, Robostreet will coordinate a third-party agency to assist Nature's Miracle in applying for California's incentive program to fund the purchase. Nature's Miracle plans to convert these electric trucks into mobile vertical farms in order to grow micro-greens and herbs which will be delivered to an end customer base including consumers and businesses. Nature's Miracle will order 150 LS 450 electric trucks from Robostreet, 40 of which will be delivered by the end of 2024, and the remaining will be delivered within one year. Nature's Miracle plans to initially deploy the Mobile E Farms in the Los Angles market. Simultaneously, Robostreet will provide the required resources to maintain its electric trucks including a photovoltaic and energy storage integrated charging station at Nature's Miracle's California warehouse.

08:28 EDT Robinhood rolls out presidential election event contracts - The company said, "Two weeks ago, we hosted hundreds of Robinhood customers in Miami at our inaugural HOOD Summit. There, we announced Robinhood Legend, and that index options and futures would be coming soon, offered by Robinhood Derivatives, LLC (RHD). Now RHD is following up on this announcement with the launch of presidential election event contracts, ahead of the November 5 general election. Event contracts allow customers to trade on the outcome of specific events, such as whether a candidate will win an election. Robinhood's presidential election event contracts will begin rolling out to a limited number of customers today. Customers must apply and meet certain criteria to be approved for a RHD account, including being a U.S. citizen and more. Once approved, customers will be able to trade based on their prediction for "who will win the 2024 presidential election." There will be two contracts to choose from-one for Kamala Harris and one for Donald Trump. We've heard from our customers that having access to the market in real time is essential - it's why, for example, we launched 24/5 trading and recently announced our plans to launch futures trading in the coming months. We believe event contracts give people a tool to engage in real-time decision-making, unlocking a new asset class that democratizes access to events as they unfold." Reference Link

08:26 EDT Nitches' InTheZone Labs opens network for distributors, affiliates, influencers - The company said, "Nitches, Inc. is thrilled to announce that InTheZone Labs has officially opened doors for distributors, affiliates, and influencers to join our mission of delivering groundbreaking cognitive and wellness solutions. As part of our commitment to expanding the reach of our products, we have launched a targeted recruitment drive, inviting professionals and influencers to leverage this exciting opportunity. The InTheZone affiliate program offers an extremely competitive 20% commission on sales, including both one-time and subscription purchases, giving participants significant earning potential. Simultaneously, we are taking a pivotal step forward in our Phase One Testing, where we've sent our initial product samples to a distinguished group of early testers, including medical doctors, doctors of chiropractic, former NFL players, and U.S. veterans. These respected individuals represent diverse user profiles, allowing us to gather comprehensive feedback across multiple demographics and use cases. Over the coming weeks, we'll release insights from this testing phase, focusing on the specific benefits of our bioceutical approach and the impact of our key ingredients."

08:22 EDT Tenon Medical regains full compliance with Nasdaq listing rules - Tenon Medical is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain board committees; Nasdaq Rule 5550(a)(2), with respect to its minimum bid price; Nasdaq Rule 5550(a)(4), with respect to number of shares in its public float; and Nasdaq Rule 5550(b), with respect to its stockholders' equity. The Company has received written confirmation from Nasdaq that it has regained compliance with each previously reported non-compliance of Nasdaq listing Rules.

08:22 EDT Ocean Power completes major milestone for Project Overmatch - Ocean Power Technologies announced that it has completed the second set of exercises of the previously announced follow-on contract as a subcontractor to EpiSci and successfully deployed several of its WAM-V autonomous surface vehicles during the Mission Autonomy Proving Grounds, MAPG, as part of Project Overmatch. Under this contract, OPT continues to ruggedize and enhance the operational capability of its autonomous maritime technologies to support the U.S. military and its allies. The first set of exercises was concluded over the summer and the completion of these most recent exercises will support immediate revenue recognition.

08:20 EDT INmune Bio to host webinar on cognitive testing using EMACC, CDR-SB - INmune Bio is hosting a Webinar on November 7, 2024. The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials," will explore the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer's Disease patients. It will also cover the regulatory landscape for Alzheimer's disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.

08:17 EDT Primech AI launches AI-powered automated toilet cleaning robot - Primech AI, a subsidiary of Primech Holdings, announces the launch of Hytron, an AI-powered automated toilet cleaning robot, now operational and enhancing hygiene standards at Temasek Polytechnic. This innovative technology introduces unprecedented levels of cleaning efficiency, setting new benchmarks in the industry.

08:16 EDT FlexShopper annoounces purchase option for 91% of Seris 2 Preferred Stock - FlexShopper has entered into a purchase option agreement with the majority holder of the Company's Series 2 Preferred Stock, in which FlexShopper has the option to redeem 91% of FlexShopper's Preferred Stock at a 50+% discount to the second quarter of 2024 liquidation preference of approximately $43 million. The discount is based upon the date of repayment and the option to purchase lasts for a one-year period. In addition, further payments to the seller of the Preferred Stock may be required based upon the purchase price in a change of control in the next 12 months or patent settlement announcements in the next 24 months. "We are excited to pursue options to redeem over 90% of our outstanding Series 2 Preferred Stock at a significant discount to its liquidation preference. We believe this opportunity will enhance shareholder value by improving our cost of capital, simplifying our capital structure and transferring $23 million of equity value to our common shareholders, representing approximately $1 per share. In addition, the redemption of our Series 2 Preferred Stock at a 50%+ discount will be highly accretive to earnings and will contribute approximately $4 million to annual operating income," said Russ Heiser.

08:13 EDT Eli Lilly, ViaNautis sign collaboration agreement for polyNaut platform - ViaNautis Bio announces a collaboration with Eli Lilly and Company. Under the terms of the agreement, ViaNautis will receive an initial upfront payment from Lilly, with the short-term potential for additional payments including research-based milestones. Further milestones and royalties would be due should specific cargo-loaded polyNaut-based products enter the clinic and reach commercialisation. This collaboration will leverage ViaNautis' platform for precise delivery of genetic cargos to prioritised tissues to address significant unmet medical needs. ViaNautis' proprietary polyNaut nanovesicles are designed to deliver genetic materials with precise targeting of specific tissues and cell types. This technology aims to improve current genetic medicine delivery, potentially transforming treatment options for various diseases.

08:13 EDT GoodRx appoints Iqvia CFO Ronald Bruehlman to board - GoodRx (GDRX) announced the election of Ronald Bruehlman to its board of directors, effective November 8. Bruehlman brings to GoodRx 39 years of finance experience in the healthcare services, industrial and petroleum industries. He currently serves as CFO of Iqvia (IQV).

08:11 EDT Kiniksa partners with Carly Pearce in expansion of Life DisRPted campaign - Kiniksa Pharmaceuticals announced a partnership with GRAMMY Award-winning singer-songwriter, Carly Pearce, as part of its Life DisRPted campaign focused on promoting early diagnosis and treatment of recurrent pericarditis. Pearce announced that she had been diagnosed with the chronic autoinflammatory disease while on tour in May 2024.

08:10 EDT Autonomix announces preliminary results from trial on ablation technology - Autonomix Medical highlighted positive preliminary results from the first five "lead-in" patients in the Company's ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. Three patients were treated with femoral access and two were treated with brachial access. Patients treated with brachial access showed no improvement in their pain scores while all patients treated with femoral access positively responded to treatment. The results presented here reflect the three patients in the responder group. Data, as previously reported, show a reduction in pain assessed using the Visual Analog Scale, VAS, from a mean pre-procedure score of 8.0 to a mean score of 1.33 at 4-6 weeks post-procedure. Additionally, all responding patients were able to completely eliminate their opioid use at 4-6 weeks post-procedure. The Trial is expected to complete enrollment by year-end 2024.

08:10 EDT DMG Blockchain Solutions acquires Reactor.xyz to offer hashrate contracts - DMG Blockchain Solutions has announced its acquisition of Reactor.xyz from Navier. Reactor is a highly-optimized solution to automate and manage hashrate contracts. Specifically unique to the software, for which there are several patent applications, is its balancing algorithm that assures hashrate delivery. A hashrate contract allows Bitcoin miners - who typically sell hashrate directly to a pool - to sell their hashrate to buyers willing to pay upfront for a specified term. These buyers are often incentivized by a discount compared to what the sellers would typically earn in bitcoin payouts over the contract period. For sellers, this arrangement provides faster access to payment, serving as a valuable treasury management tool akin to factoring receivables. Reactor's key enabling technology assures that the hashrate transferred from seller to buyer meets the contract's requirements for the entirety of its term. This technology allows for highly granular hashrate delivery, ranging from 100 TH/s to over 1 EH/s. Having been developed and operating over the past several years, Reactor is a proven solution. Terra Pool is an ideal platform to significantly expand Reactor's reach. With Terra Pool having the ability to offer a large hashrate supply powered by carbon neutral energy, buyers will have access to a much larger supply than previously available. Furthermore, DMG believes that carbon neutral bitcoin may command a premium, and the same advantage could apply to carbon neutral hashrate. Terra Pool clients would thus have the option to either mine carbon neutral bitcoin or sell carbon neutral hashrate contracts, offering multiple avenues to benefit from participating in a carbon neutral pool.

08:07 EDT Lightbridge shares findings from three technical papers at TopFuel 2024 - Lightbridge shares findings from three technical papers presented at the TopFuel 2024 Conference in Grenoble, France. These papers, produced by Massachusetts Institute of Technology, MIT, Structural Integrity Associates, SIA, and Lightbridge further validate the enhanced safety and performance of Lightbridge Fuel, particularly its improved performance under extreme conditions. Key findings from the MIT study: The MIT findings confirm that Lightbridge Fuel operates at significantly lower temperatures compared to traditional fuel, with improved safety margins that can enable power uprate opportunities while maintaining safe operation of the fuel. The study emphasized Lightbridge Fuel's potential for power uprates, enabling reactors to generate more power safely. Key Findings from the SIA Study: In summary, the Lightbridge metallic fuel offers improved safety performance over UO2 fuel in accident conditions by maintaining lower temperatures and reducing oxidation. Summary of the Lightbridge paper presented at the TopFuel 2024 Conference: These studies have confirmed the expected performance of Lightbridge Fuel and provided a basis for continued development and future regulatory licensing.

08:05 EDT Baker Hughes awarded contracts to supply Petrobras with flexible pipe systems - Baker Hughes (BKR) announced Monday significant contracts with Petrobras (PBR) to provide 77 km of flexible pipe systems to be deployed in Brazil's pre-salt fields. The agreement was signed Oct. 15, 2024, following an open tender. The multi-year project includes risers and flowlines for hydrocarbon production and associated gas and water injection with support for equipment storage, maintenance and installation. Delivery is scheduled to begin in mid-2026, and the equipment will be utilized across Petrobras' Buzios, Libra, Berbigao, Sururu and Sepia fields.

08:03 EDT CareCloud pays off credit line, signs updated credit facility agreement - CareCloud has fully paid down its credit facility line with Silicon Valley Bank, achieving a key 2024 objective. Additionally, CareCloud requested and secured a reduction in its borrowing fees and lowered its overall revolving credit facility limit. Pursuant to the Company's Ninth Loan Modification Agreement, dated October 25, 2024, with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, the Company continues to maintain an unused, but available, credit facility line of $10 million. The information contained in this press release is a summary of certain relevant portions of the Agreement and Form 8-K, which are filed with Securities and Exchange Commission.

08:02 EDT AbbVie to acquire Aliada Therapeutics for $1.4B in cash - AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier-crossing technology to address challenging central nervous system diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta antibody in development for the treatment of Alzheimer's disease. Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4B in cash, subject to certain customary adjustments. This transaction is expected to close in 4Q2024, subject to regulatory approvals and other customary closing conditions.

07:47 EDT ARway announce results of pilot with George Mason University - ARway.ai announced "the success" of its pilot with George Mason University. The initiative, aimed at launching an augmented reality app for first-generation ADVANCE students, has achieved significant milestones and will be extended into 2025. George Mason University, in collaboration with ARway.ai, is developing a smartphone app to support first-generation ADVANCE students through an augmented reality campus tour. Designed to ease the transition for students transferring from Northern Virginia Community College, the app offers a virtual tour of George Mason's Fairfax Campus, addressing a significant need for clear navigation and community integration for incoming students. The AR tour, led by project co-directors Kelly Schrum and Graziella Pagliarulo McCarron, both professors at George Mason University, leverages ARway's technology. The app provides interactive GPS tracking, indoor visual positioning, and an intuitive geolocation feature, enabling students to navigate campus facilities, such as gender-neutral bathrooms, elevators, and student support centers, with ease. Currently in development, the app will be expanded from SUB I to additional campus locations, including Fenwick Library and the Johnson Center. Funded by George Mason's Office of the Provost and the state-supported 4-VA@Mason initiative, this project aligns with the ADVANCE program's mission.

07:38 EDT Bowman Consulting to lead program management for The Aurora Highlands - Bowman Consulting Group announced that it has been selected to provide program management services for The Aurora Highlands, a 3,000-acre master planned community in Aurora, Colorado. As program manager, Bowman will oversee the design of more than $500 million worth of infrastructure, in addition to the refinement of short- and long-term development plans, the management of other engineering and design consultants as well as the coordination of land use and public enhancements. The Company will also work to manage bid packages, assist with selecting contractors and work with the City of Aurora on infrastructure entitlements and design approvals.

07:34 EDT Johnson & Johnson's Tremfya shows efficacy in Crohn's disease Phase 3 study - Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya - guselkumab -, the first and only IL-23 inhibitor, demonstrating "robust" results in subcutaneous induction and maintenance therapy. The findings demonstrated "significant" clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.1 More than half of patients treated with Tremfya achieved clinical remission versus those in the placebo group - 56.1% vs. 21.4% -. Endoscopic response was achieved in 41.3% of patients treated with Tremfya induction therapy versus 21.4% in the placebo group. Greater improvements in clinical remission were seen as early as Week 4 with Tremfya vs. placebo, demonstrating rapid onset of action. The rate of clinical remission was more than three times higher with both maintenance doses of Tremfya vs. placebo. Endoscopic response was achieved in 44.3% and 51.3% of patients in the Tremfya 100 mg SC q8w group and 200 mg SC q4w group respectively versus 6.8% in the placebo group. The results reinforced the safety profile of Tremfya. Tremfya received FDA approval in September 2024 for the treatment of adults with moderately to severely active ulcerative colitis and an application for the treatment of moderately to severely active CD is currently under FDA review. Regulatory applications seeking approval of Tremfya for adults with moderately to severely active UC and with moderately to severely active CD have been submitted in Europe.

07:25 EDT WeRide announces official listing on Nasdaq - WeRide was officially listed on the Nasdaq Global Select Market under the ticker symbol "WRD." Upon listing, WeRide became the world's first publicly listed universal autonomous driving technology company and the first publicly listed Robotaxi company. The initial public offering price was set at $15.5 per American depositary share. If the underwriters fully exercise the granted option, the Company will issue a total of 8,903,760 ADSs. The total proceeds from the public offering, combined with $320 million concurrent private placement, are expected to amount to $458.5 million, assuming the underwriters of the initial public offering fully exercise their option.

07:18 EDT International Petroleum announces results of normal course issuer bid - International Petroleum announced that IPC repurchased a total of 111,400 IPC common shares during the period of October 21 to 25, 2024 under IPC's normal course issuer bid / share repurchase program. IPC's NCIB, announced on December 1, 2023, is being implemented in accordance with the Market Abuse Regulation No 596/2014 and Commission Delegated Regulation No 2016/1052 and the applicable rules and policies of the Toronto Stock Exchange and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of October 21 to 25, 2024, IPC repurchased a total of 87,500 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC.

07:17 EDT Unicycive presents on development progress of oxylanthanum carbonate - Unicycive Therapeutics announced that multiple presentations were delivered at the American Society of Nephrology Kidney Week 2024 that highlighted the extensive development progress for both oxylanthanum carbonate and UNI-494. In addition to the presentations at ASN, preclinical studies for both OLC and UNI-494 were recently featured in two publications. "Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models" was published in the Pharmaceutical Chemistry Journal. "Evaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model" was published in EC Pharmacology and Toxicology. ASN KIDNEY WEEK PRESENTATIONS: Title: Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia: Summary: This late-breaking poster describes the pivotal Phase 2 open-label, single-arm, multicenter, multidose study in adult patients with CKD with hyperphosphatemia receiving maintenance hemodialysis. The aim of the study was to assess the tolerability and safety of OLC at doses that achieve satisfactory serum phosphate control of less than or equal to5.5 mg/dl. Most patients who achieved the target serum phosphate did so with less than or equal to1500 mg/day and the percent of patients with serum phosphate less than or equal to5.5 mg/dl increased from 59% at Screening to 91% at the end of titration. OLC was safe and well-tolerated with adverse events commonly seen in this patient population and with other phosphate binders. The use of OLC enabled adequate control of serum phosphate in greater than90% of patients who entered maintenance. Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat: Summary: This study evaluated the effects of OLC plus tenapanor on urinary phosphate excretion in rats on a high phosphorus diet. The study showed that the combination of OLC and tenapanor may support a pronounced inhibition of intestinal phosphate absorption by leveraging two distinct mechanisms of action: OLC, an intestinal phosphate binder, and tenapanor, a sodium/hydrogen exchanger blocker that diminishes transcellular phosphate absorption. The results demonstrated that the OLC plus tenapanor combination achieved a much more pronounced reduction in urinary phosphate excretion as compared to OLC alone and 3.3 times greater than tenapanor alone. In addition, the OLC plus tenapanor combination exhibited four- to seven-fold more synergistic effects compared to the sevelamer plus tenapanor combination. The study demonstrated potent effects of the novel lanthanum-based phosphate binder OLC and found that OLC plus tenapanor has synergistic, rather than additive, effects in rats. Title: UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics: Summary: The poster described the results from the single ascending dose cohorts from the Phase 1 study evaluating safety, tolerability, and pharmacokinetics of UNI-494 capsules administered to healthy volunteers. The study was a single-center, double-blind, placebo-controlled, randomized study that enrolled up to 40 subjects in 5 cohorts of 8 subjects each. Safety assessments and pharmacokinetics and systemic exposure of UNI-494 and its metabolites were evaluated. The data demonstrated that a single dose of 10-160 mg of UNI-494 capsules were safe and well-tolerated, and that UNI-494 was rapidly converted to nicorandil and the exposure to nicorandil increased in a dose-proportional manner. Therapeutic levels of nicorandil were achieved at 160 mg of UNI-494. This rapid conversion of UNI-494 to nicorandil and 1-cyclohexylethylamine indicates a potential for a fast-acting therapy for the prevention of Delayed Graft Function and other acute kidney injury clinical conditions. Title: Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats Summary: The poster presented the results from a study evaluating the in vivo efficacy of intravenous (IV) UNI-494 when administered therapeutically after unilateral renal ischemia-reperfusion in a rat model of AKI, which is a well-established model of DGF. The study showed that single IV doses of 10 mg/kg of UNI-494 administered after I/R significantly reduced serum and urinary AKI markers and improved proximal tubular injury scores. Specifically, a single IV dose of 10 mg/kg of UNI-494 improved key kidney functional markers, the tubular injury marker neutrophil gelatinase-associated lipocalin, and proximal tubular injury scores. These data indicate therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression.

07:14 EDT Monte Rosa announces global license agreement with Novartis - Monte Rosa Therapeutics (GLUE) announced a global exclusive development and commercialization license agreement with Novartis (NVS) to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in an ongoing Phase 1, single ascending dose/multiple ascending dose healthy volunteer study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa remains responsible for completion of the ongoing Phase 1 clinical study of MRT-6160.i

07:12 EDT Gilat Satellite receives over $4M order from U.S. Department of Defense - Gilat Satellite Networks announced that the US Department of Defense awarded another contract for more than $4M to Gilat's US-based subsidiary, DataPath, for DKET 3421 terminals, portable satcom hubs that provide the flexibility, capacity, connectivity, and control needed to ensure mission success anywhere in the world. The orders are expected to be delivered during the first half of 2025.

07:09 EDT Aecon Group to acquire United Engineers & Constructors for $33M - Aecon Group has entered into a definitive purchase agreement to acquire United Engineers & Constructors, a nuclear and conventional power contractor headquartered in Mount Laurel, New Jersey, from affiliates of CriticalPoint Capital, for a purchase price of $33M, payable in cash at closing. United's management and operational teams will join Aecon upon closing of the Transaction, which is subject to customary adjustments and closing conditions, including obtaining all necessary regulatory approvals. Founded in 1905, United provides end-to-end engineering, planning, and program and construction management services to nuclear and conventional power clients in the United States and Canada. United maintains a strategic focus on nuclear power plant life extensions and developing small modular reactor and power generation projects. The majority of United's revenues are conducted under Master Service Agreements and are recurring in nature. Aecon and United have a proven relationship and are collaboratively engaged as joint venture partners in executing steam generator replacement work and fuel channel and feeder replacements on six units at the Bruce Nuclear Generating Station in Ontario.

07:08 EDT Telesat, Airbus begin collaboration to integrates Lightspeed into HBCplus - Telesat (TSAT) announced the signing of a Memorandum of Understanding, MOU, with Airbus (EADSY) to collaborate on the integration of the Telesat Lightspeed low earth orbit, LEO, network within the Airbus HBCplus Ka-band solution portfolio. Airbus launched its HBCplus satellite connectivity solution as a supplier-furnished line-fit catalogue option and also for retrofit on all Airbus programs. Airbus and Telesat will work together to address user terminal integration for HBCplus installations that are capable of providing Telesat Lightspeed services.

07:08 EDT Aura Minerals, Bluestone Resources enter definitive arrangement agreement - Bluestone Resources (BBSRF) and Aura Minerals (ORAAF) announce that they have entered into a definitive arrangement agreement pursuant to which Aura will acquire all of the issued and outstanding common shares of Bluestone by way of a plan of arrangement under the Business Corporations Act. Aura will be acquiring a 100% interest in Bluestone's Cerro Blanco gold project and the adjacent Mita Geothermal project. Bluestone valued at approximately C$ 0.50 per Bluestone Share, representing a 51% premium to spot and a 40% premium to the volume weighted average price of the Bluestone Shares on the TSX Venture Exchange for the 25 day period ending October 24th, 2024, to be paid in a combination of cash or Aura shares on closing and a contingent value right, representing a total enterprise value of up to $74.3 million. Pursuant to the Transaction, for each Bluestone share held, Bluestone shareholders will be able to elect to receive upfront consideration on closing consisting of either: a cash payment of C$0.287; or 0.0179 of an Aura common share, subject to proration; or a combination of both. The upfront consideration will be subject to maximum aggregate Aura shares issuable of 1,363,272. Bluestone shareholders will also receive a CVR providing the holder thereof with the potential to receive a cash payment of up to an aggregate amount of C$0.2120, for each Bluestone share, payable in three equal annual installments upon Cerro Blanco achieving commercial production. The Transaction was unanimously approved by Bluestone's Board of Directors and by Aura's Board of Directors. The Transaction will be subject to the approval by Bluestone securityholders at a special meeting of Bluestone securityholders and subject to the receipt of certain regulatory, court, TSXV and Toronto Stock Exchange approvals, and other closing conditions customary in transactions of this nature. Cerro Blanco is a near surface high grade gold deposit, in Jutiapa, Guatemala. An N.I. 43-101 technical report on the project was produced and filed in April 2022. The Mita Geothermal project is an advanced-stage, renewable energy project licensed to produce up to 50 megawatts of power. As previously disclosed by Bluestone, on June 17, 2024, Bluestone received a notice from the Guatemalan Ministry of Environment challenging the approval procedure that approved the surface mining method for Cerro Blanco. Bluestone has the view that environmental permit amendment met and exceeded the terms of reference provided by the MARN, and it adhered to Guatemalan law. Aura intends, upon closing of the transaction, to evaluate the alternatives for a future potential development of Cerro Blanco. The Transaction will be completed pursuant to a court-approved plan of arrangement under the Business Corporations Act. The Transaction will be subject to the approval of: at least 66- 2/3% of the votes cast by holders of Bluestone Shares; 66- 2/3% of the votes cast by holders of Bluestone Shares and options, voting together as a single class; and "minority approval" in accordance with Multilateral Instrument 61-101, at a special meeting of Bluestone securityholders to be held to consider the Transaction. In addition to Bluestone securityholder approval, the Transaction is also subject to the receipt of certain regulatory, court, TSXV and TSX approvals, and other closing conditions customary in transactions of this nature. The Arrangement Agreement includes customary deal protections, including a non-solicitation covenant on the part of Bluestone and a right for Aura to match any competing offer that constitutes a superior proposal. The Arrangement Agreement includes a termination fee of US$2 million, payable by Bluestone under certain circumstances. All officers and directors of Bluestone, along with Nemesia S.a.r.l. and CD Capital Natural Resources Fund III LLP, owning in aggregate approximately 39% of the outstanding Bluestone Shares, have entered into voting support agreements pursuant to which they have agreed, among other things, to vote their Bluestone Shares in favour of the Transaction. Closing is expected to occur in January 2025, subject to satisfaction of the conditions to closing.

07:04 EDT Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300 - Tyra Biosciences announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a Phase 2 clinical trial of Tyra-300 for children with achondroplasia. TYRA-300 is a potential first-in-class, investigational, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4. Tyra-300 is also being evaluated for metastatic urothelial cancer in the ongoing SURF301 study. BEACH301 will be a Phase 2 study evaluating Tyra-300 in children ages 3 to 10 with achondroplasia with open growth plates. The primary objectives of this study will be to assess safety and tolerability in children with achondroplasia and evaluate change from baseline in annualized growth velocity to determine the dose for further development. Tyra is also planning exploratory assessments of clinical outcomes such as functional improvements, changes in the spine, and quality of life measures. In July 2023 and January 2024, the FDA granted Orphan Drug Designation and Rare Pediatric Designation to Tyra-300, respectively, for the treatment of achondroplasia.

07:02 EDT Lithium Ionic joins United Nations Global Compact Initiative - Lithium Ionic has joined the United Nations Global Compact. This membership reflects Lithium Ionic's commitment to advancing the United Nations Sustainable Development Goals and embracing the Ten Principles, which emphasize human rights, labour, environmental responsibility, and anti-corruption practices. As a member of this global network of over 25,000 companies, Lithium Ionic reinforces its dedication to addressing key global challenges, including climate action, gender equality, poverty reduction, and biodiversity protection. Participation in the UNGC requires annual reporting on progress, ensuring transparency and ongoing dedication toward making a meaningful impact.

06:51 EDT Eli Lilly announces results from two, multi-year mirikizumab studies - Eli Lilly announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases, or IBD, ulcerative colitis, or UC, and Crohn's disease. Data from the two trials - LUCENT-3 in moderately to severely active UC and VIVID-2 in moderately to severely active Crohn's disease - will be presented at the American College of Gastroenterology, or ACG, annual meeting from October 25-30 in Philadelphia. Mirikizumab is an interleukin-23p19 antagonist that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Inflammation due to the overactivation of the IL-23 pathway plays a critical role in pathogenesis of UC and Crohn's disease. Inflammation from UC and Crohn's disease can lead to disruptive symptoms, including bowel urgency, that can result in decreased health-related quality of life and potentially irreversible complications for patients if left untreated. Mirikizumab is approved in the United States for the treatment of moderately to severely active UC in adults and is under review with the FDA for moderately to severely active Crohn's disease. In LUCENT-3, mirikizumab helped patients with moderately to severely active UC achieve long-term outcomes, including histologic-endoscopic mucosal remission, defined as mucosal healing. Mirikizumab also provided sustained benefit across symptomatic, clinical, endoscopic and histologic endpoints for up to three years, regardless of previous failure to TNF inhibitors, tofacitinib or other biologics. Among those who achieved clinical remission with mirikizumab at one year in the LUCENT-2 study, the following results were achieved based upon observed case analysis after an additional two years of treatment: 81% of patients maintained long-term clinical remission; 82% achieved long-term endoscopic remission; 72% had mucosal healing; 79% achieved corticosteroid-free clinical remission and patients demonstrated a sustained clinically meaningful improvement in symptom score reduction for bowel urgency. These results were also evaluated using a modified non-responder imputation. Among patients receiving mirikizumab in the LUCENT-3 study, 7.4% of patients reported a serious adverse event, or AE, while 5.3% discontinued treatment due to an AE. The long-term safety profile in patients with moderately to severely active UC was consistent with the already known safety profile of mirikizumab. New data from patients in the Phase 2 program who enrolled into the VIVID-2 long-term extension study showed that patients with moderately to severely active Crohn's disease treated with mirikizumab maintained high rates of clinical and endoscopic remission over time. The following results were achieved based upon observed case analysis after an additional three years of treatment: 96% of patients had clinical response as measured by the Crohn's Disease Activity Index; 87% were in clinical remission as measured by CDAI; 76% had endoscopic response and 54% of patients were in endoscopic remission. These results were also evaluated using a modified non-responder imputation and are presented in the About the Mirikizumab Crohn's Disease Program section below. Among these patients who enrolled into the VIVID-2 long-term extension study, 8.5% reported a serious AE and 1.9% discontinued treatment due to an AE. The long-term safety profile in patients with moderately to severely active Crohn's disease was consistent with the already known safety profile of mirikizumab. Omvoh was approved by the FDA in October 2023 as the first IL23p19 antagonist for the treatment of moderately to severely active UC in adults and is also approved in 44 countries around the world. Lilly submitted marketing applications for mirikizumab in Crohn's disease around the globe, including in the U.S., Canada, Europe, Japan and China. Additional global regulatory submissions are planned. Additionally, Lilly has a combination study in UC with mirikizumab and eltrekibart, a humanized monoclonal antibody that binds to the seven ligands that signal through the CXCR1 and CXCR2 chemokine receptors involved in neutrophil movement to sites of inflammation. There are also ongoing studies in both UC and Crohn's disease with MORF-057, a selective oral small molecule alpha-4/beta-7 integrin inhibitor that may improve outcomes and expand treatment options for people with IBD.

06:35 EDT Uranium Royalty acquires existing royalty on uranium projects in Canada - Uranium Royalty announced that it acquired an existing royalty on the Millennium and Cree Extension Uranium Projects in Saskatchewan, Canada from a third-party industrial gas company for total cash consideration of $6M. The acquired royalty is a net profit interest, or NPI, of 10% on an approximate 20.6955% participating interest in the projects. The royalty becomes payable after recovery of all qualifying preproduction expenditures incurred after the establishment of the royalty. The millennium project hosts an indicated mineral resource of 75.9M pounds U3O8 at an average grade of 2.39% U3O8 and an Inferred Resource of 29.0 Mlbs U3O8 at an average grade of 3.19% U3O8, which places it among the largest undeveloped uranium projects globally. Cameco Corporation, the operator of the projects, submitted an Environmental Impact Statement application in 2009 for the project, anticipated to produce 150,000 to 200,000 tons of ore per year with a submitted potential mine life of 10 years. The acquisition of the royalty on these two projects provides URC exposure to approximately 12,800 hectares of ground in the highly prospective Athabasca Basin, with well-respected operators, and in one of the top mining jurisdictions in the world.

06:27 EDT Fennec announces three executive appointments - Fennec Pharmaceuticals appointed Pierre Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer and Christiana Cioffi as Chief Strategy Officer, all of which become effective immediately. Pierre Sayad is a biopharmaceutical executive with more than 22 years building and leading organizations. During his tenure in the industry, Sayad has launched nine novel drugs across 14 therapeutic areas. He also served as senior vice president, business development and global medical affairs at the International Myeloma Foundation. Prior to his appointment at Fennec, he served as COO and Interim CMO at Zephyr Labz. Terry Evans has more than 25 years of experience with companies, including Currax Pharmaceuticals, Horizon Therapeutics, Graceway Pharmaceuticals, and Medicis. Prior to his appointment at Fennec, he was CEO of UNITE Pharma Trade Advisors. Christiana Cioffi brings more than 20 years of experience in strategy, leadership and culture building focused primarily in oncology, rare disease, and hematology therapeutic areas at companies, including Shield Therapeutics, Stemline Therapeutics, EUSA Pharma, Karyopharm Therapeutics, Servier and Abbott Laboratories. Prior to her appointment at Fennec, Christiana served as a strategic advisor and leadership coach at Disruptify Consulting.

06:08 EDT AstraZeneca's Fasenra approved in EU for EGPA - AstraZeneca's Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis, EGPA. EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on positive results from the MANDARA Phase III trial, published in The New England Journal of Medicine. In the trial, nearly 60% of Fasenra-treated patients achieved remission, which was comparable to mepolizumab-treated patients.3 Data also showed 41% of Fasenra-treated patients fully tapered off oral corticosteroids.

06:02 EDT Modine Manufacturing opens new facility in Calgary - Modine announced the opening of a new 250,000 square foot facility in Calgary, Canada. The facility will manufacture Airedale by Modine precision cooling equipment to meet the increased demand from data center customers, particularly in the hyperscale market. Modine acquired Canada-based Scott Springfield Manufacturing in February and promptly broke ground on a third facility to manufacture advanced air handling units for hyperscale data center customers under the Airedale by Modine brand. This new facility expands Modine's ability to provide customers with cooling equipment from a global manufacturing footprint that includes facilities in Spain, the UK, and the U.S. The first Airedale by Modine units from the new Calgary facility are expected to be delivered by the end of 2024.

05:37 EDT Philips sees FY24 adjusted EDITDA margin 11.5% - The company said, "The significant deterioration in China demand leads to an updated comparable sales growth outlook range of 0.5-1.5% for the full year 2024. Comparable sales growth outside of China remains within the 3-5% range. Adjusted EBITA margin is expected to be around 11.5%, the upper end of the range, with free cashflow at around EUR 0.9 billion, at the lower end of the range. Within an ongoing challenging macro environment, Philips remains focused on successfully executing its three-year plan to drive operational improvement and create value with sustainable impact. The uncertainties signaled in earlier quarters have intensified in China and are expected to continue. The outlook excludes the potential impact of the ongoing Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice."

05:25 EDT Volvo, Daimler Truck sign binding agreement for joint venture - As announced in May this year, Volvo Group and Daimler Truck intend to create a joint venture to develop a common software-defined vehicle platform and dedicated truck operating system, providing the basis for future software-defined commercial vehicles. The two companies have now signed a binding agreement to establish the joint venture and are working towards setting up the company that will be headquartered in Gothenburg, Sweden. The software-defined vehicle platform will enable Volvo Group and Daimler Truck and potential other future customers of the joint venture to provide stand-alone digital vehicle functions for their products. The joint venture's activities will include the specification and procurement of centralized high-performance control units dedicated for commercial vehicles and capable of handling large amounts of data. The new company will develop an operating system and tools which vehicle manufacturers can use as a basis to develop their own differentiating digital vehicle features. This will decouple software and hardware development cycles in the future and enable customers to purchase and update digital applications wirelessly 'over the air', ultimately enhancing customer efficiency and experience. Volvo Group and Daimler Truck will remain competitors and continue to differentiate their complete product and services offerings, including their respective digital solutions. The transaction for the joint venture is expected to be completed in the first half of 2025, subject to obtaining all required regulatory approvals.

05:19 EDT WTW secures insurance license in the Kingdom of Saudi Arabia - WTW announced it has secured an insurance license to act as an insurance broker in the Kingdom of Saudi Arabia, or K.S.A. Talal Omar Bahafi has been appointed as the new head of insurance broking, WTW Saudi Arabia, based in the Kingdom of Saudi Arabia.

05:08 EDT DigitalBridge to acquire Yondr Group, terms undisclosed - DigitalBridge announced it has reached an agreement to acquire Yondr Group, a developer and operator of hyperscale data centers, through one of its managed investment funds. The company has more than 420MW of capacity committed to hyperscalers, with additional land to support a total potential capacity of over 1GW. The DigitalBridge Fund's strategic investment will drive the development of data centers, backed by revenue streams from investment-grade clients. Yondr will continue to operate as an independent company within DigitalBridge's portfolio. The deal is expected to close in early 2025, subject to customary closing conditions. Citi served as Yondr's exclusive financial advisor, with White & Case LLP as its legal counsel. DigitalBridge engaged Linklaters as legal advisors, Deloitte for financial and tax due diligence, Ramboll for technical expertise, and Nomura for financing support.